Advertisement

Pneumo News

, Volume 11, Issue 6, pp 30–34 | Cite as

Neue Agenzien und Anwendungsgebiete

Die blühende Zukunft der Immuntherapie bei Allergien

  • Ina HaaslerEmail author
  • Christian Taube
fortbildung

Bei der Allergen-Immuntherapie (AIT) rührt sich was. Es sind inzwischen neue Therapeutika verfügbar, etwa Antikörper, rekombinante Proteine oder Peptide, die nur 13 bis 17 Aminosäuren lang sind. Auch verschiedene neue sublinguale Therapien stehen bereit. Zudem ist es nun möglich, Nahrungsmittelallergien durch frühzeitige Induktion der oralen Toleranz in der Säuglingszeit vorzubeugen.

Literatur

  1. 1.
    Pfaar O, Demoly P, Gerth van Wijk R et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014;69(7):854–67CrossRefGoogle Scholar
  2. 2.
    Demoly P, Emminger W, Rehm D et al. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2016;137(2):444–51.e8CrossRefGoogle Scholar
  3. 3.
    Durham SR, Yang WH et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117(4):802–9CrossRefGoogle Scholar
  4. 4.
    Maloney J, Bernstein DI, Nelson H et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol. 2014;112(2):146–53.e2CrossRefGoogle Scholar
  5. 5.
    Biedermann T, Kuna P, Panzner P et al. The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2019;143(3):1058–66.e6CrossRefGoogle Scholar
  6. 6.
    Couroux P, Patel D, Armstrong K et al. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin Exp Allergy. 2015;45(5):974–81CrossRefGoogle Scholar
  7. 7.
    Klimek L, Pfaar O, Worm M. New opportunities for allergen immunotherapy using synthetic peptide immuno-regulatory epitopes (SPIREs). Expert Rev Clin Immunol. 2016;12(10):1123–35CrossRefGoogle Scholar
  8. 8.
    Worm M, Patel D, Creticos PS. Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis. Expert Opin Investig Drugs. 2013;22(10):1347–57CrossRefGoogle Scholar
  9. 9.
    Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010(8):Cd001186Google Scholar
  10. 10.
    Mosbech H, Deckelmann R, de Blay F et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2014;134(3):568–75.e7CrossRefGoogle Scholar
  11. 11.
    de Blay F, Kuna P, Prieto L et al. SQ HDM SLIT-tablet (ALK) in treatment of asthma—post hoc results from a randomised trial. Respir Med. 2014;108(10):1430–7CrossRefGoogle Scholar
  12. 12.
    Virchow JC, Backer V, Kuna P et al. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. JAMA. 2016;315(16):1715–25CrossRefGoogle Scholar
  13. 13.
    Agache I, Lau S, Akdis CA et al. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. Allergy. 2019;74(5):855–73CrossRefGoogle Scholar
  14. 14.
    Gupta RS, Springston EE, Warrier MR et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics. 2011;128(1):e9–17CrossRefGoogle Scholar
  15. 15.
    Venter C, Maslin K, Patil V et al. The prevalence, natural history and time trends of peanut allergy over the first 10 years of life in two cohorts born in the same geographical location 12 years apart. Pediatr Allergy Immunol. 2016;27(8):804–11CrossRefGoogle Scholar
  16. 16.
    Chinthrajah RS, Hernandez JD, Boyd SD et al. Molecular and cellular mechanisms of food allergy and food tolerance. J Allergy Clin Immunol. 2016;137(4):984–97CrossRefGoogle Scholar
  17. 17.
    Kim KS, Hong SW, Han D et al. Dietary antigens limit mucosal immunity by inducing regulatory T cells in the small intestine. Science. 2016;351(6275):858–63CrossRefGoogle Scholar
  18. 18.
    Du Toit G, Roberts G, Sayre PH et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015;372(9):803–13CrossRefGoogle Scholar
  19. 19.
    Valovirta E, Petersen TH, Piotrowska T et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018;141(2):529–38.e13CrossRefGoogle Scholar
  20. 20.
    Humbert M, Beasley R, Ayres J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–16CrossRefGoogle Scholar
  21. 21.
    Brandstrom J, Vetander M, Lilja G et al. Individually dosed omalizumab: an effective treatment for severe peanut allergy. Clin Exp Allergy. 2017;47(4):540–50CrossRefGoogle Scholar
  22. 22.
    Tsabouri S, Tseretopoulou X, Priftis K, Ntzani EE. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol Pract. 2014;2(3):332–40.e1CrossRefGoogle Scholar
  23. 23.
    Agarwal A, Spath D, Sherris DA et al. Therapeutic Antibodies for Nasal Polyposis Treatment: Where Are We Headed? Clin Rev Allergy Immunol. 2019;  https://doi.org/10.1007/s12016-019-08734-zGoogle Scholar
  24. 24.
    Ryan D, Gerth van Wijk R, Angier E et al. Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy. Allergy. 2018;73(4):827–36CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Universitätsmedizin Essen, Ruhrlandklinik, Klinik für Pneumologie, Westdeutsches Lungenzentrum am Universitätsklinikum EssenEssenDeutschland

Personalised recommendations